{
    "sponsor_name": "",
    "study_acronym": "",
    "tested_imp": "apixaban",
    "comparative_drug": "dalteparin",
    "study_type": "interventional",
    "interventional_study_phase": "",
    "study_design": "randomized, open-label, parallel-group, non-inferiority trial",
    "aim_of_study": "To assess the non-inferiority of oral apixaban compared to subcutaneous low molecular weight heparin (LMWH) dalteparin for the treatment of newly diagnosed proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) in patients with cancer.",
    "target_disease": "cancer-associated venous thromboembolism (proximal DVT and/or PE)",
    "type_of_randomization": "",
    "randomization_stratification": [],
    "apixaban_dosing": "10 mg BID for first 7 days, then 5 mg BID",
    "dalteparin_dosing": "200 IU/kg daily for first month, then 150 IU/kg daily",
    "apixaban_supply_form": "",
    "dalteparin_supply_form": "pre-filled syringes",
    "scheduled_visits": [
        "Screening (up to specified days before Day 1)",
        "Day 1",
        "Month 1",
        "Month 2",
        "Month 3",
        "Month 4",
        "Month 5",
        "Month 6 (end of intervention)",
        "Month 7 (follow-up)"
    ],
    "primary_efficacy_outcome": "Composite of recurrent VTE (proximal DVT, non-fatal PE, and VTE-related death) during the 6-month intervention period.",
    "secondary_efficacy_outcomes": [
        "Composite of major and clinically relevant non-major (CRNM) bleeding, and all bleeding events",
        "Incidence of major bleeding (MB) and clinically relevant non-major bleeding (CRNMB)",
        "Rates of major bleeding in patient subgroups",
        "Incidence of the Major Venous Thromboembolism (VTE) endpoint",
        "Efficacy in subgroups defined by cancer type and VTE presentation",
        "Individual components of the primary efficacy outcome",
        "Symptomatic recurrence of VTE",
        "All-cause death",
        "Composite of the primary efficacy outcome plus major bleeding",
        "Composite of the primary efficacy outcome plus all-cause death",
        "Composite of the primary efficacy outcome plus major bleeding plus all-cause death",
        "Any major cardiovascular event, fatal or non-fatal, including acute myocardial infarction or ischemic stroke",
        "All venous thromboembolic events, including splanchnic vein thrombosis and cerebral vein thrombosis",
        "Permanent early discontinuation of the study drug due to safety reasons",
        "Quality of Life (QoL) according to the Anti-Clot Treatment Scale (ACTS)"
    ],
    "primary_safety_outcome": "Composite of major and clinically relevant non-major (CRNM) bleeding events during the 6-month intervention period.",
    "secondary_safety_outcomes": [
        "Incidence of major bleeding (MB) and clinically relevant non-major bleeding (CRNMB)",
        "Rates of major bleeding in patient subgroups",
        "Permanent early discontinuation of the study drug due to safety reasons"
    ],
    "maximum_sample_size_per_arm": 0,
    "recommended_inclusion_criteria": [],
    "recommended_exclusion_criteria": []
}